Balances concentration with syringe precision | | 50mg | 5mL | 10mg/mL | 0.5mL (50 units) | 1.0mL (100 units) | Lower concentration improves measurement accuracy but uses solution faster | | 100mg | 2mL | 50mg/mL | 0.1mL (10 units) | 0.2mL (20 units) | Higher vial amount extends total doses but requires same precision as 50mg/1mL | | 100mg | 4mL | 25mg/mL | 0.2mL (20 units) | 0.4mL (40 units) | Optimal for multi-week protocols
(published around 2010) and related work, rats treated with BPC 157 at approximately 10 mcg/kg body weight intraperitoneally showed histologically confirmed improved Achilles tendon repair compared to controls
Your body shifts toward using fat as fuel
Date of Opening: Clearly mark the date the vial was first punctured on the vial label
Clinical Efficacy Uncertainties The most significant limitation is the failure to demonstrate consistent efficacy in human applications: Discontinued clinical development in 2007 after 24-week Phase III trial showed insufficient weight loss Inconsistent dose-response relationship, with higher doses paradoxically less effective than lower doses Failure to produce clinically meaningful results when combined with diet and exercise interventions No peer-reviewed publications demonstrating sustained weight loss or metabolic benefits in humans Mechanistic Understanding Gaps Fundamental aspects of AOD-9604s mechanism remain unclear despite extensive research: Primary receptor target unidentified after decades of investigation Relationship between 3-minute plasma half-life and prolonged biological effects unexplained Role of metabolites versus parent peptide in mediating effects unknown Tissue-specific mechanisms and distribution patterns incompletely characterized Long-Term Safety Considerations Critical safety questions remain unanswered beyond the 24-week trial duration: Chronic use effects beyond 6 months completely unstudied even in animal models Potential long-term metabolic adaptations or tolerance development unknown Effects on reproductive function and development inadequately characterized Interaction potential with common medications unexamined Regulatory & Competitive Sport Status FDA Position AOD-9604 has never received FDA approval for any indication: Not approved for human therapeutic use in the United States Not recognized as Generally Recognized As Safe (GRAS) for dietary supplement use (contrary to some marketing claims) Not legally available for medical compounding in the United States Clinical development terminated by sponsor company in 2007 due to lack of efficacy The FDA has not issued specific guidance on AOD-9604, but it falls under unapproved new drug regulations and cannot be legally marketed for human consumption
In pernicious anaemia, the immune system mistakenly attacks the gastric parietal cells that produce intrinsic factor, leading to B12 deficiency over time
